Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
M. Preusser reports on brain tumour studies results presented at ASCO 2019. He details some new data from the CATNON trial focusing on molecular subtybes such as IDH mutated anaplastic glioma, and shows intracranial responses with larotrectinib in NTRK fusion positive glioma and also in patients with brain matastases from other tumours.
He also reports on results from a randomised multicentre trial in meningioma.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
